Professor Geoffrey Farrell

Geoffrey Farrell graduated in medicine from University of Tasmania in 1970, and trained in gastroenterology and hepatology at Royal Prince Alfred Hospital (with Neil Gallagher) and Royal Brisbane Hospital (with Lawrie Powell). After completing his MD with Lawrie Powell, he was awarded an NHMRC CJ Martin Fellowship for postdoctoral research at UCSF (with Rudi Schmid and John Gollan). In 1980, he returned to Sydney to establish a Liver Research Group at Westmead Hospital which became The Storr Liver Unit in 1993; GF was Director until Jan 2006. He then accepted his current position of Professor of Hepatic Medicine within ANU Medical School. Among many leadership roles, he has been President ASMR 1987, President Gastroenterological Society of Australia (GESA) 2000-2001, and Head, Department of Medicine, University of Sydney 1996-1997.

Geoff Farrell's research interests are in non-alcoholic steatohepatitis, ischemia-reperfusion injury, hepatocellular carcinoma, viral hepatitis and drug-induced liver injury. He has published 4 books, including the first on NAFLD (and its second, 2013, version), and written more than 220 scientific papers and 130 reviews/chapters/editorials. His work is very highly cited, with an H-index >60, more than 40 articles cited >100 times (5 cited >500 times), average citation 33/paper, and 22 articles the subject of editorials or editorial comment. He has been CIA on an NHMRC Program Grant and CCRE, an NIH RO1 for study of hepatitis C pathogenesis, and has held more than 28 NHMRC project grants.

Among several honours and awards, he has received the Distinguished Research Prize of GESA 2003, the Eric Susman Prize for Medical Research 1988, RACP, and delivered the inaugural Hy Zimmerman lecture at AASLD 2002, the Georges Brohée medal lecture at WCOG, Shanghai 2013, as well as 6 other named orations at overseas meetings. He has supervised more than twenty five Doctoral Research Students (PhD or MD), eight of whom have won between them 10 highly competitive Young Investigator Awards. Until December 2012 he was Editor-in-Chief of the Journal of Gastroenterology and Hepatology during which the Impact Factor rose from 1.6 to 3.3.

Research interests

Gastroenterology and Hepatology

  • Ioannou, G, Van Rooyen, D, Savard, C et al 2015, 'Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH', Journal of Lipid Research, vol. 56, no. 2, pp. 277-285.
  • Farrell, G 2014, 'Should we lower lipids in nonalcoholic fatty liver disease?', Clinical Gastroenterology and Hepatology, vol. 12, no. 1, pp. 152-155.
  • LEGRY, V, Van Rooyen, D, LAMBERT, B et al 2014, 'Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice', Clinical Science, vol. 127, no. 7-8, pp. 507-518.
  • Zhang, X, Shen, J, Man, K et al 2014, 'CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis', Journal of Hepatology, vol. 61, no. 6, pp. 1365-1375.
  • Teoh, N & Farrell, G 2014, 'Cholesterol Augments High Fat Diet in Accelerating Liver Carcinogenesis: Roles of NASH, Oxidative Stress, DNA Damage and Hepatocyte Proliferation', Gastroenterology, vol. 146, no. 5, pp. S927-S927.
  • Farrell, G 2014, 'Insulin Resistance, Obesity, and Liver Cancer', Clinical Gastroenterology and Hepatology, vol. 12, no. 1, pp. 117-119.
  • Wu, J, Shadbolt, F, Teoh, N et al 2014, 'Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C', Journal of Gastroenterology and Hepatology, vol. 29, no. 6, pp. 1258-1264.
  • Chen, S, Teoh, N, Chitturi, S et al 2014, 'Coffee and Non-Alcoholic Fatty Liver Disease: Brewing evidence for hepatoprotection?', Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 435-441.
  • Farrell, G, Mridha, A, Yeh, M et al. 2014, 'Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype', Liver International, vol. 34, no. 7, pp. 1084-1093.
  • Teoh, N, Ajamieh, H, Wong, H et al 2014, 'Microparticles Mediate Hepatic Ischemia-Reperfusion Injury and Are The Targets of Diannexin (ASP8597)', PLOS ONE (Public Library of Science), vol. 9, no. 9, pp. e104376-e104376.
  • Gan, L, Van Rooyen, D, Teoh, N et al 2014, 'Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent', Journal of Hepatology, vol. 61, no. 6, pp. 1376-1384.
  • Van Rooyen, D, Gan, L, Yeh, M et al 2013, 'Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome', Journal of Hepatology, vol. 59, no. 1, pp. 144-152.
  • Savard, C, Tartaglione, E, Kuver, R et al 2013, 'Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis', Hepatology, vol. 57, no. 1, pp. 81-92.
  • Chitturi, S & Farrell, G 2013, 'Adverse Effects of Hormones and Hormone Antagonists on the Liver', in (ed.), Drug-Induced Liver Disease, Elsevier Inc., Unknown, pp. 605-620.
  • Farrell, G, Wong, V & Chitturi, S 2013, 'NAFLD in Asia-as common and important as in the West', Nature Reviews. Gastroenterology & Hepatology, vol. 10, no. 5, pp. 307-318.
  • Pok, S, Wen, V, Shackel, N et al 2013, 'Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis', Journal of Gastroenterology and Hepatology, vol. 28, no. 9, pp. 1545-1554.
  • Heydet, D, Chen, L, Larter, C et al 2013, 'A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice', Developmental Neurobiology, vol. 73, no. 1, pp. 1-13.
  • Larter, C, Yeh, M, Haigh, W et al. 2013, 'Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease', Obesity, vol. 21, no. 6, pp. 1189-1199.
  • Larter, C, Yeh, M, Van Rooyen, D et al 2012, 'Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis', Journal of Gastroenterology and Hepatology, vol. 27, no. 2, pp. 341-350.
  • Farrell, G 2012, 'JGH and me: a long and winding road-reflections of an outgoing Editor-in-Chief', Journal of Gastroenterology and Hepatology, vol. 27, no. 12, pp. 1768-1771.
  • Farrell, G, Van Rooyen, D, Gan, L et al 2012, 'NASH is an inflammatory disorder: Pathogenic, prognostic and therapeutic implications', Gut and Liver, vol. 6, no. 2, pp. 149-171.
  • Ajamieh, H, Farrell, G, Wong, H et al 2012, 'Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation', Journal of Gastroenterology and Hepatology, vol. 27, no. 8, pp. 1353-1361.
  • Chitturi, S & Farrell, G 2012, 'Lessons from Lumiracoxib: Are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?', Journal of Gastroenterology and Hepatology, vol. 27, no. 6, pp. 993-994.
  • Shen, B, Chu, E, Zhao, G et al 2012, 'PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice', British Journal of Cancer, vol. 106, no. 9, pp. 1486-1494.
  • Farrell, G & Van Rooyen, D 2012, 'Liver cholesterol: Is it playing possum in NASH?', American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 303, no. 1, pp. G9-G11.
  • Wu, C, Farrell, G & Yu, J 2012, 'Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma', Journal of Gastroenterology and Hepatology, vol. 27, no. 11, pp. 1665-1669.
  • Hashimoto, E, Tokushige, K & Farrell, G 2012, 'Histological features of non-alcoholic fatty liver disease: what is important?', Journal of Gastroenterology and Hepatology, vol. 27, no. 1, pp. 5-7.
  • Yeomans, N & Farrell, G 2012, 'The JGH foundation: facilitating education and research in the Asia-Pacific', Journal of Gastroenterology and Hepatology, vol. 27, no. 10, pp. 1545-1545.
  • Gan, L, Chitturi, S & Farrell, G 2011, 'MECHANISMS AND IMPLICATIONS OF AGE RELATED CHANGES IN THE LIVER NONALCOHOLIC FATTY LIVER DISEASE IN THE ELDERLY', Current Gerontology and Geriatrics Research, vol. 2011, no. 831536, pp. 831536-831536.
  • Chitturi, S & Farrell, G 2011, 'IDENTIFYING WHO IS AT RISK OF DRUG INDUCED LIVER INJURY IS HUMAN LEUKOCYTE ANTIGEN SPECIFICITY THE KEY', Hepatology, vol. 53, no. 1, pp. 358-362.
  • Farrell, G & Chitturi, S 2011, 'Drug-induced liver injury: What would a liver doctor do?', Medicine Today, vol. 12, no. 9, pp. 39-48.
  • Van Rooyen, D & Farrell, G 2011, 'Editorial: SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH', Journal of Gastroenterology and Hepatology, vol. 26, no. 5, pp. 789-792.
  • Chitturi, S, Wong, V & Farrell, G 2011, 'Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground', Journal of Gastroenterology and Hepatology, vol. 26, no. 1, pp. 163-172.
  • Poustchi, H, Farrell, G, Strasser, S et al 2011, 'Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?', Hepatology, vol. 54, no. 6, pp. 1998-2004.
  • Bell-Anderson, K, Aouad, L, Williams, H et al 2011, 'Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice', International Journal of Obesity, vol. 35, no. 12, pp. 1539-1548.
  • Van Rooyen, D, Larter, C, Haigh, W et al 2011, 'Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis', Gastroenterology, vol. 141, no. 4, pp. 1393-U850.
  • Manchanayake, J, Chitturi, S, Nolan PhD, C et al. 2011, 'Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease', Journal of Gastroenterology and Hepatology, vol. 26, no. 3, pp. 510-516.
  • Chitturi, S & Farrell, G 2011, 'Drug induced liver disease', in Eugene R. Schiff, Willis C. Maddrey, Michael F. Sorrell (ed.), Schiff's Diseases of the Liver, Eleventh Edition, John Wiley & Sons Ltd., England, pp. 703-783.
  • Yabas, M., Teh, C. E., Frankenreiter, S., Lal, D., Roots, C. M., Whittle, B., Andrews, D. T., Zhang, Y., Teoh, N. C., Sprent, J., Tze, L. E., Kucharska, E. M., Kofler, J., Farell, G. C., Bröer, S., Goodnow, C. C. & Enders, A. 2011. ATP11C is critical for the internalization of phosphatidylserine and differentiation of B lymphocytes. Nature Immunology, 12, 441-449.
  • Teoh, N, Pyakurel, P, Dan, Y et al 2010, 'Induction of p53 Renders ATM-Deficient Mice Refractory to Hepatocarcinogenesis', Gastroenterology, vol. 138, no. 3, pp. 1155-U451.
  • Teoh, N, Farrell, G & Chan, H 2010, 'Individualisation of antiviral therapy for chronic hepatitis C', Journal of Gastroenterology and Hepatology, vol. 25, no. 7, pp. 1206-1216.
  • Fan, J, Farrell, G & Fan, J 2010, 'Editorial: Does non-alcoholic fatty liver disease predispose patients to type 2 diabetes in the absence of obesity?', Journal of Gastroenterology and Hepatology, vol. 25, no. 2, pp. 223-225.
  • Teoh, N, Williams, J, Hartley, J et al 2010, 'Short-Term Therapy with Peroxisome Proliferation-Activator Receptor-Agonist Wy-14,643 Protects Murine Fatty Liver Against Ischemia-Reperfusion Injury', Hepatology, vol. 51, no. 3, pp. 996-1006.
  • Farrell, G, ed., 2010, In our 25th year - when we were two! A word from the Editor-in-Chief.
  • Larter, C, Chitturi, S, Heydet, D et al 2010, 'A fresh look at NASH pathogenesis. Part 1: The metabolic movers', Journal of Gastroenterology and Hepatology, vol. 25, no. 4, pp. 672-690.
  • Farrell, G & Teoh, N 2010, 'Abnormal liver function tests', Australian Doctor, vol. 9 April 2010, pp. 29-36.
  • Farrell, G 2010, 'PNPLeAse get the fats right: Does lipogenesis or lipolysis cause NASH?', Hepatology, vol. 52, no. 3, pp. 818-821.
  • Farrell, G, Chan, H, Yuen, M et al 2010, 'Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements', Journal of Gastroenterology and Hepatology, vol. 25, no. 4, pp. 657-663.
  • Teoh, N, Chitturi, S & Farrell, G 2010, 'Liver Disease caused by drugs', in Mark Feldman, Lawrence S Friedman, Lawrence J. Brandt (ed.), Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Elsevier, USA, pp. 1413-1431.
  • Farrell, G, Larter, C, Hou, J et al 2009, 'Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression', Journal of Gastroenterology and Hepatology, vol. 24, pp. 443-452.
  • Hashimoto, E & Farrell, G 2009, 'Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?', Journal of Gastroenterology and Hepatology, vol. 24, pp. 501-508.
  • Farrell, G, Yeomans, N & Crawford, D 2009, 'Fifty years of Australian gastroenterology and hepatology: A golden era of contributions to the region', Journal of Gastroenterology and Hepatology, vol. 24, pp. 1579-1586.
  • Farrell, G & Fan, J 2009, 'Epidemiology of non-alcoholic fatty liver disease in China', Journal of Hepatology, vol. 50, pp. 204-210.
  • Chitturi, S & Farrell, G 2009, 'Clues from the carotids: An appraisal of cardiovascular disease risk in non-alcoholic fatty liver disease', Journal of Gastroenterology and Hepatology, vol. 24, pp. 1315 - 1317.
  • Yuen, M, Hou, J, Chutaputti, A et al 2009, 'Hepatocellular Carcinoma in the Asia pacific region', Journal of Gastroenterology and Hepatology, vol. 24, pp. 346-353.
  • Farrell, G 2009, 'The liver and the waistline: Fifty years of growth', Journal of Gastroenterology and Hepatology, vol. 24 Suppl 3, pp. S105-S118.
  • Fan, J & Farrell, G 2009, 'Prevention of hepatocellular carcinoma in nonviral-related liver diseases', Journal of Gastroenterology and Hepatology, vol. 24, pp. 712-719.
  • Phung, N, Pera, N, Farrell, G et al 2009, 'Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis', International Journal of Molecular Medicine, vol. 24, pp. 171-180.
  • Heydet, D, Larter, C & Farrell, G 2009, 'Central mechanism of hyperphagia in a mouse model of obesity-related liver disease', Journal of Gastroenterology and Hepatology, pp. A277.
  • Larter, C, Yeh, M, Van Rooyen, D et al 2009, 'Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice', Journal of Gastroenterology and Hepatology, vol. 24, pp. 158 - 1668.
  • Amarapurkar, D, Han, K, Chan, H et al 2009, 'Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region', Journal of Gastroenterology and Hepatology, vol. 24, pp. 955-961.
  • Ueno, Y, Sollano, J & Farrell, G 2009, 'Prevention of hepatocellular carcinoma complicating chronic hepatitis C', Journal of Gastroenterology and Hepatology, vol. 24, pp. 531-536.
  • Chitturi, S & Farrell, G 2008, 'Hepatotoxic slimming aids and other herbal hepatotoxins', Journal of Gastroenterology and Hepatology, vol. 23, no. 3, pp. 366-373.
  • Larter, C, Yeh, M, Haigh, W et al 2008, 'Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways', Journal of Hepatology, vol. 48, no. 4, pp. 638-647.
  • Farrell, G, Teoh, N & McCuskey, R 2008, 'Hepatic Microcirculation in Fatty Liver Disease', The Anatomical Record, vol. 291, pp. 684-692.
  • Larter, C, Yeh, M, Cheng, J et al 2008, 'Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation', Journal of Gastroenterology and Hepatology, vol. 23, no. 2, pp. 267-275.
  • Larter, C, Yeh, M, Williams, J et al 2008, 'MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes', Hepatology, vol. 49, no. 3, pp. 407-416.
  • Fan, J, Shi, J, Wu, R et al 2008, 'Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection', Journal of Gastroenterology and Hepatology, vol. 23, no. 9, pp. 1419-1425.
  • Farrell, G, Chitturi, S, Lau, G et al 2007, 'Guidelines for the Assessment and Management of Non-alcoholic Fatty Liver Disease in the Asia-Pacific Region: Executive Summary', Journal of Gastroenterology and Hepatology, vol. 22, pp. 775-777.
  • Chitturi, S, Farrell, G & Chitturi, S 2007, 'TNF-alpha as therapeutic target in NASH: tried, but not yet proven', Journal of Gastroenterology and Hepatology, vol. 22, pp. 613-614.
  • Teoh, N, Ito, Y, Field, J et al 2007, 'Diannexin, a Novel Annexin V Homodimer, Provides Prolonged Protection Against Hepatic Ischemia-Reperfusion Injury in Mice', Gastroenterology, vol. 133, pp. 632-646.
  • Chitturi, S, Farrell, G & Chitturi, S 2007, 'Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health', Journal of Gastroenterology and Hepatology, vol. 22, pp. 961-969.
  • dela Pena, A, Leclercq, I, Williams, J et al 2007, 'NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis.', Journal of Hepatology, vol. 46, pp. 304-313.
  • Chitturi, S, Farrell, G, Hashimoto, E et al 2007, 'Non-alcoholic Fatty Liver Disease in the Asia-Pacific Region: Definitions and Overview of Proposed Guidelines', Journal of Gastroenterology and Hepatology, vol. 22, pp. 778-787.
  • Farrell, G 2007, 'New hepatitis C guidelines for the Asia-Paciï¬?c region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection', Journal of Gastroenterology and Hepatology, vol. 22, pp. 607-610.
  • Farrell, G, Desmond, P & Wong, B 2007, 'Agent Orange: Your new look JGH (the improvements go deeper than the cover)', Journal of Gastroenterology and Hepatology, vol. 22, pp. 1167-1173.
  • Farrell, G & Yeomans, N 2007, 'Emerging leaders of gastroenterology and hepatology in the Asia-Paciï¬?c region', Journal of Gastroenterology and Hepatology, vol. 22, pp. 961-962.
  • Larter, C & Farrell, G 2006, 'Insulin Resistance, Adiponectin, Cytokines in NASH: Which is the Best Target to Treat?', Journal of Hepatology, vol. 44, no. 2, pp. 253-261.
  • Teoh, N & Farrell, G 2006, 'Management of chronic viral hepatitis B infection: a new era of disease control', Internal Medicine Journal, vol. 36, pp. 100 -113.
  • Arsov, T, Larter, C, Nolan PhD, C et al. 2006, 'Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice', Biochemical and Biophysical Research Communications, vol. 342, pp. 1152-1159.
  • Farrell, G & Larter, C 2006, 'Non-alcoholic Fatty Liver Disease: From Steatosis to Cirrhosis', Hepatology, vol. 43, no. 2 (supp 1), pp. S99-S112.
  • Farrell, G, ZHANG, H, Hou, J et al 2006, 'Mechanisms of apoptosis in dietary steatohepatitis: roles of cytokines, nutrient and ER stress', Journal of Gastroenterology and Hepatology, vol. A4, p. 318.
  • Teoh, N & Farrell, G 2006, 'Liver Diseases Caused by Drugs', in (ed.), Sleisenger and Fordtran's Textbook of Gastrointestinal Disease (8th ed), Elsevier, United States, pp. 1807 - 1843.
  • Teoh, N, Field, J & Farrell, G 2006, 'Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice', Journal of Hepatology, vol. 45, pp. 20 - 27.
  • Arsov, T, Larter, C, Nolan, C et al 2006, 'Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice', Biochemical and Biophysical Research Communications, vol. 342, no. 4, pp. 1152-59.
  • Farrell, G, George, J, Hall, P et al, eds, 2005, Fatty liver disease: NASH and related disorders, Blackwell Publishing Ltd, London.
  • Farrell, G 2005, 'Signalling links in the liver: Knitting SOCS with fat and inflammation', Journal of Hepatology, vol. 43, no. 1, pp. 193-196.
  • Teoh, N, Field, J, Sutton, J et al 2004, 'Dual role of tumor necrosis factor-a in hepatic ischemia reperfusion injury: studies in TNF-a knockout mice', Hepatology, vol. 39, pp. 412 - 421.
  • Hui, J, Hodge, A, Farrell, G et al 2004, 'Beyond Insulin Resistance in NASH: TNF-alpha or Adiponectin?', Hepatology, vol. 40, no. 1, pp. 46-54.
  • Teoh, N, Leclercq, I, Pena, A et al 2003, 'Low-Dose TNF-a Protects Against Hepatic Ischemia-Reperfusion Injury in Mice: Implications for Preconditioning', Hepatology, vol. 37, no. 1, pp. 118 - 128.
  • Teoh, N & Farrell, G 2003, 'Hepatic ischaemia reperfusion injury. Pathogenic mechanisms and basis for protection', Journal of Gastroenterology and Hepatology, vol. 18, pp. 891 - 902.
  • Teoh, N, Leclercq, I, Pena, A et al 2003, 'Low-dose TNF-alpha is protective against hepatic ischemia-reperfusion injury in mice: Implications for preconditioning', Hepatology, vol. 37, no. 1, pp. 118-128.
  • Ip, E, Farrell, G, Robertson, G et al 2003, 'Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice', Hepatology, vol. 38, no. 1, pp. 123-132.
  • Hui, J, Sud, A, Farrell, G et al 2003, 'Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression', Gastroenterology, vol. 125, pp. 1695-1704.
  • Teoh, N & Farrell, G 2003, 'Hepatotoxicity associated with non-steroidal anti-inflammatory drugs', Clinics in Liver Disease, vol. 7, no. 2, pp. 401 - 413.